Genes Highlight Who'll Benefit From Multiple Myeloma Treatment With Venclexta
By Dennis Thompson HealthDay Reporter
WEDNESDAY, Dec. 4, 2024 -- Genetic tests can show which patients with the blood cancer multiple myeloma should respond to targeted therapy, a new study finds.
A special six-gene pattern can help predict who are more likely to respond well to Venclexta (venetoclax), a pill that promotes natural cell death among cancer cells, researchers said.
“By knowing which patients might benefit the most, we can customize treatments to improve their chances of success,” said researcher Alessandro Lagana, an assistant professor of oncological sciences at the Icahn School of Medicine at Mount Sinai, in New York City.
Multiple myeloma is a cancer of blood plasma cells, according to the American Cancer Society. About 35,780 new cases of multiple myeloma are expected to be diagnosed in 2024, and it will kill about 12,540 U.S. adults.
Venclexta keeps cancer cells from dodging apoptosis, the body process that causes old or damaged cells to self-destruct.
Multiple myeloma cells carry a protein called BCL-2 that keeps the cell from triggering apoptosis. Venclexta inhibits BCL-2, restoring natural cell death for these cancer cells.
The U.S. Food and Drug Administration approved Venclexta in 2018, but up to now it’s been unclear which patients would most benefit from the drug.
For this study, researchers analyzed the genetics of 58 patients treated with Venclexta between 2017 and 2021.
They discovered a specific genetic pattern “with higher scores being consistently associated with less favorable responses,” the research team wrote.
“Doctors could use genetic testing to choose the best candidates for venetoclax treatment,” Lagana said in a Icahn news release.
Researchers also found that Venclexta worked best when paired with a CKD7 inhibitor, another type of drug that promotes natural cell death.
“Combining venetoclax with CDK7 inhibitors might help more patients respond positively, especially those who might not respond well to venetoclax alone,” Lagana said. “For patients, this research means someday they could receive more personalized treatment plans based on their genetic information, leading to better outcomes.”
Researchers next plan to confirm their findings in a larger group of patients, and to test the combined use of Venclexta and CDK7 inhibitors in clinical trials.
The new study was published in December issue of the journal Blood Neoplasia.
Sources
- Mount Sinai, news release, Nov. 27, 2024
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted December 2024
Read this next
China Donates $500M to WHO as U.S. Pulls Back Support
THURSDAY, May 22, 2025 — China has promised to give $500 million to the World Health Organization (WHO) over the next five years, positioning itself to become the...
Additional Breast Cancer Scans Can Triple Detection In Women With Dense Breasts
THURSDAY, May 22, 2025 — Louise Duffield, 60, was relieved to receive a normal mammogram result in 2023, but agreed to undergo an additional MRI scan recommended as part of...
Want To Deter Teen Vaping? Make Devices Boring, Study Says
THURSDAY, May 22, 2025 — Making vape devices boring could help deter teens and young adults from picking up the e-cigarette habit, a new study says. Vape devices currently...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.